UnitedHealth Group, the infamous insurance group that has been in the news thanks to the Luigi Mangione trial, is being investigated by the U.S. Department of Justice (DOJ) for criminal fraud. The company that became the poster boy for corporate corruption after the murder of its CEO Brian Thompson by Mangione, may now find itself on trial and be indicted for fraud.
The Wall Street Journal reported on Wednesday that the DOJ is carrying out a criminal investigation into UnitedHealth Group for possible Medicare fraud. UnitedHealth said it had not been notified by the DOJ about the “supposed criminal investigation reported,” and the company stood by “the integrity of our Medicare Advantage program.” The stock fell 8% in after-hours trade following the report.
Medicare is a U.S. federal health insurance program primarily designed for individuals aged 65 and older, although it also covers younger people with disabilities or specific conditions like end-stage renal disease. The program is divided into several parts: Part A covers hospital stays, skilled nursing, hospice, and some home health care; Part B covers outpatient services, such as doctor visits and preventive care; Part C, or Medicare Advantage, allows beneficiaries to receive their benefits through private insurance plans, often with additional coverage; and Part D provides prescription drug coverage through private insurers.
READ: Nearly half of America’s youth finds UnitedHealthcare CEO’s killing acceptable (December 20, 2024)
Medicare helps reduce the financial burden of healthcare for seniors, covering a wide range of essential medical services. However, it doesn’t cover all costs, such as long-term care or dental services, and individuals may need additional insurance or coverage options to fill in the gaps. The program plays a crucial role in supporting the health and well-being of older adults.
The new investigation reportedly follows broader scrutiny into the Medicare Advantage program. If found guilty, UnitedHealth could face hefty fines, legal fees, and potential damage to the company’s reputation. This scrutiny could also lead to tighter regulations in the health insurance industry. Beyond the immediate financial impact, the investigation might undermine trust with consumers and investors, affecting the company’s stock performance and long-term business operations.
UnitedHealth Group revealed on Tuesday that its CEO Andrew Witty is stepping down due to personal reasons. Witty would remain a senior advisor as he is replaced by former CEO and longtime company leader Stephen Hemsley, who has been board chair since 2017. The health insurance company has also suspended its annual forecast due to surging medical costs, sending shares plunging nearly 18% to a four-year low.